Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
LYRA
Lyra Therapeutics, Inc.
Chronic rhinosinusitis is an inflammatory/immune-driven condition; Lyra's approach targets immunology therapeutics via localized delivery.
|
$5.94M |
$3.60
-0.42%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB develops oncology-focused cell-based therapies (Cell-in-a-Box encapsulation) aligned with Biotech - Oncology.
|
$5.64M |
$0.95
+14.10%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$5.54M |
$1.15
-0.86%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
PAVM
PAVmed Inc.
PAVmed's biopharma expansion targets oncology assets, aligning with Biotech - Oncology.
|
$5.40M |
$7.30
-1.08%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$5.24M |
$0.92
+2.22%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$5.16M |
$0.19
-7.66%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.07M |
$1.55
-0.26%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$4.90M |
$0.82
-4.64%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$4.67M |
$0.63
-5.53%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$4.61M |
$2.96
+1.72%
|
|
XAIR
Beyond Air, Inc.
UNO program for solid tumors places Beyond Air in oncology-focused biotech pipelines.
|
$4.33M |
$0.94
+13.69%
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$4.32M |
$5.94
-0.17%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$3.99M |
$1.28
+1.98%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$3.70M |
$0.11
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.59M |
$0.39
+1.86%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$3.59M |
$0.61
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$3.49M |
$1.19
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$3.02M |
$0.02
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$3.02M |
$2.16
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$2.69M |
$1.22
-2.80%
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.54M |
$1.18
+3.98%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$2.34M |
$4.37
-7.32%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$2.22M |
$0.06
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.11M |
$0.01
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.10M |
$0.29
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.98M |
$1.79
-2.97%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$1.63M |
$9.03
+1.35%
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.55M |
$0.91
+0.13%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.31M |
$0.02
|
Showing page 24 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
